Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:9/6/2011

NEW YORK, Sept. 6, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following September 2011 investor conferences:

Stifel Nicolaus Healthcare Conference (Boston, MA)
Wednesday, September 7, 2011
10:55am ET

Rodman & Renshaw Annual Global Investment Conference (New York, NY)
Monday, September 12, 2011
10:50am ET

UBS Global Life Sciences Conference (New York, NY)
Tuesday, September 20, 2011
11:00am ET

JMP Securities Sixth Annual Healthcare Conference (New York, NY)
Tuesday, September 27, 2011
10:30am ET

Each of the presentations will be live audio webcast, and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. Archived versions of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects other signal transduction pathways, including the JNK pathway, believed to be associated with cell death, growth, differentiation and survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) ag
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
4. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
5. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
8. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
11. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
... Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex Pharmaceuticals (ASX: ... clinical data relevant to the development,strategy for ... T315I mutation in Philadelphia-positive leukemias",by researchers Simona ... Italy (Haematologica Volume 92, pages 401-404) offers,insight ...
Cached Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... A short, preoperative team briefing prior to cardiac ... - improves communication and reduces errors and costs, according ... Mayo researchers believe this is the first such study ... preoperative briefings on specific disruptions to surgery. Disruptions were ...
... fires, elected officials and city managers gather to prepare ... The Los Angeles County Department of Public Health today ... at your Doorstep," designed to educate elected officials and ... More than one hundred participants attended the workshop from ...
... of the recently updated 2009 editions of two ... products industry. According to Market Scope, this is ... market. New anti-VEGF therapies are successfully treating vision-threatening ... been largely untreatable. Investigational devices are promising to ...
... Systems, Inc. today announced that the Frisco Independent ... Model 615 on four occasions during the first ... President of Operations.(Logo: http://www.newscom.com/cgi-bin/prnh/20051215/OXYSURELOGO ... in its first month of implementation, only solidifies ...
... Affordable Wristbands Access to Emergency Info LAHAINA, Hawaii, ... new product originally intended for athletes, yet appealing ... simple personal safety solution. The XtremeSportsID band is ... medical alert symbol, a unique 8-digit code, and ...
... software now availableINDIANAPOLIS, May 26 ProSolv CardioVascular, ... the commercial availability of Synapse(TM) ProSolv(R) ... integration with QLAB advanced quantification software from Philips ... been designed to enhance clinical workflow, help improve ...
Cached Medicine News:Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:County and City Leaders Coordinate to Just Be Ready 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 4Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 2Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 3Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 4Health News:New Wristband May Save Lives 2Health News:New Wristband May Save Lives 3Health News:ProSolv Version 4.0.2 Makes Commercial Debut at ASE 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: